Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas.

ScientificWorldJournal · 2012 · PMC3432352 · PMID 22973169

Europe PMC DOI

hedged sentences

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantP < 0.0001actually significant

This difference was highly significant ( χ 2 = 23.70, P < 0.0001).

also in 132,142 other papers

showed a trendno p-value reported

We showed a trend towards longer median overall survival for patients with primary pancreatic NECs (7.0 months) versus patients with nonpancreatic NECs (2.9 months) after receiving TMZ as monotherapy.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.